Clearmind Medicine Set to Execute 1-for-40 Reverse Stock Split Next Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Should l Buy CMND?
Source: NASDAQ.COM
Reverse Share Split Announcement: Clearmind Medicine Inc. has announced a 1-for-40 reverse share split, effective December 15, 2025, to comply with Nasdaq's Minimum Bid Price Rule, reducing outstanding shares from approximately 59.99 million to 1.50 million.
Clinical Trials Progress: The company's lead drug candidate, CMND-100 (MEAI), is currently in Phase I/IIa clinical testing for alcohol use disorder, with positive early results prompting the continuation of the study.
Additional Research: Clearmind is also developing other psychedelic-derived compounds aimed at treating binge behaviors, depression, and metabolic disorders, which are in preclinical stages.
Stock Performance: CMND's stock has fluctuated between $0.10 and $2.18 over the past year, closing at $0.114 before dropping 23% in premarket trading to $0.08.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clearmind Medicine Reports Positive Clinical Trial Results
- Clinical Trial Progress: Clearmind Medicine Inc. announced additional positive safety topline results from the second cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, reinforcing the encouraging safety and tolerability profile established in the first cohort, indicating the drug's potential in treating Alcohol Use Disorder.
- Therapeutic Potential: CMND-100 is viewed as a potentially safe, non-hallucinogenic treatment that does not require adjunct psychotherapy, aiming to address significant unmet needs in the Alcohol Use Disorder space, potentially offering new options for patients.
- Market Reaction: In pre-market trading, CMND shares are priced at $1.36, up 0.76% from the previous trading day, reflecting market recognition of the company's positive clinical results, which may attract more investor interest.
- Future Plans: Backed by these positive clinical results, Clearmind Medicine plans to gather further evidence to support the safety and efficacy of CMND-100, thereby advancing its application in the treatment of Alcohol Use Disorder.
See More
Clearmind Reports Positive Safety Results for AUD Drug in Phase I/IIa Trial
- Clinical Trial Progress: Clearmind Medicine has completed treatment for six patients in the second cohort of its FDA-approved CMND-100 trial, further confirming the drug's safety and tolerability with no serious adverse events, indicating its potential as a treatment for Alcohol Use Disorder (AUD).
- Multicenter Study: The trial is conducted at leading institutions such as Johns Hopkins University and Tel Aviv Sourasky Medical Center, emphasizing CMND-100's global research capabilities and enhancing the company's competitiveness in the psychedelic pharmaceutical sector.
- Support from Data Monitoring Board: The unanimous approval from the Data and Safety Monitoring Board (DSMB) to advance the second cohort reflects confidence in CMND-100's safety and efficacy, potentially accelerating the progression to subsequent clinical phases.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as needed, demonstrating the company's long-term strategic positioning and market competitiveness in psychedelic drug development.
See More
Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales
- Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
- Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
- Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
- Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
See More
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Restoration: Clearmind Medicine confirmed on December 30, 2025, that its common shares have maintained a closing price above $1 for the last 10 consecutive trading days, successfully regaining compliance with Nasdaq Listing Rule 5550(a)(2), indicating positive progress in stock price stability.
- Price Volatility Context: Previously, Clearmind was notified on December 4, 2025, of non-compliance due to its share price being below $1 for over 30 consecutive trading days, and this compliance restoration is expected to enhance investor confidence and attract more capital inflow.
- Market Reaction Expectations: With the restoration of compliance, Clearmind is likely to improve its market image and bolster investor confidence in its future growth potential, particularly in light of its commitment to developing novel psychedelic treatment solutions.
- Strategic Development Focus: Clearmind is currently focused on developing neuroplastic drugs targeting under-treated health issues and will continue to seek patent protection to enhance its intellectual property portfolio, further strengthening its competitiveness in the biotech sector.
See More
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Regained: Clearmind Medicine received confirmation from Nasdaq on December 30, 2025, that its share price exceeded $1 for the last 10 consecutive trading days, thereby regaining compliance with Nasdaq Listing Rule 5550(a)(2) and resolving previous compliance issues.
- Price Fluctuation Context: The company was notified on December 4, 2025, of non-compliance due to its common shares closing below $1 for over 30 consecutive trading days, highlighting market concerns regarding its stock price volatility.
- Future Growth Potential: Clearmind focuses on developing novel neuroplastogen-derived therapeutics, particularly for alcohol use disorder, which is expected to attract more investor interest in its innovative treatment solutions, further stabilizing and potentially increasing the company's stock price.
- Intellectual Property Strategy: The company currently holds 19 patent families and 31 granted patents, with plans to seek additional patents to enhance its market competitiveness, demonstrating a long-term strategic vision in the biotechnology sector.
See More
Clearmind Medicine Advances CMND-100 Clinical Trials for Alcohol Use Disorder
- Clinical Trial Progress: Clearmind successfully initiated its FDA-approved Phase I/IIa trial for CMND-100 at prestigious institutions like Yale and Johns Hopkins, achieving first-in-human dosing and demonstrating a favorable safety profile, marking a significant advancement in treating Alcohol Use Disorder.
- Safety Endorsement: The Data and Safety Monitoring Board unanimously approved the continuation of the clinical trial, reinforcing CMND-100's safety profile and laying a solid foundation for future data readouts, which boosts investor confidence.
- Global Footprint Expansion: Clearmind strengthened its intellectual property portfolio with multiple international patent filings targeting various indications, including weight loss and depression, showcasing the company's strategic positioning across multiple therapeutic areas.
- Future Outlook: Looking ahead to 2026, Clearmind aims to advance its pipeline, generate additional clinical data, and explore strategic opportunities to maximize shareholder value and patient impact, demonstrating its long-term commitment to the market.
See More
Clearmind Medicine Reports Positive Clinical Trial Results
- Clinical Trial Progress: Clearmind Medicine Inc. announced additional positive safety topline results from the second cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, reinforcing the encouraging safety and tolerability profile established in the first cohort, indicating the drug's potential in treating Alcohol Use Disorder.
- Therapeutic Potential: CMND-100 is viewed as a potentially safe, non-hallucinogenic treatment that does not require adjunct psychotherapy, aiming to address significant unmet needs in the Alcohol Use Disorder space, potentially offering new options for patients.
- Market Reaction: In pre-market trading, CMND shares are priced at $1.36, up 0.76% from the previous trading day, reflecting market recognition of the company's positive clinical results, which may attract more investor interest.
- Future Plans: Backed by these positive clinical results, Clearmind Medicine plans to gather further evidence to support the safety and efficacy of CMND-100, thereby advancing its application in the treatment of Alcohol Use Disorder.
See More
Clearmind Reports Positive Safety Results for AUD Drug in Phase I/IIa Trial
- Clinical Trial Progress: Clearmind Medicine has completed treatment for six patients in the second cohort of its FDA-approved CMND-100 trial, further confirming the drug's safety and tolerability with no serious adverse events, indicating its potential as a treatment for Alcohol Use Disorder (AUD).
- Multicenter Study: The trial is conducted at leading institutions such as Johns Hopkins University and Tel Aviv Sourasky Medical Center, emphasizing CMND-100's global research capabilities and enhancing the company's competitiveness in the psychedelic pharmaceutical sector.
- Support from Data Monitoring Board: The unanimous approval from the Data and Safety Monitoring Board (DSMB) to advance the second cohort reflects confidence in CMND-100's safety and efficacy, potentially accelerating the progression to subsequent clinical phases.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as needed, demonstrating the company's long-term strategic positioning and market competitiveness in psychedelic drug development.
See More
Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales
- Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
- Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
- Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
- Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
See More
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Restoration: Clearmind Medicine confirmed on December 30, 2025, that its common shares have maintained a closing price above $1 for the last 10 consecutive trading days, successfully regaining compliance with Nasdaq Listing Rule 5550(a)(2), indicating positive progress in stock price stability.
- Price Volatility Context: Previously, Clearmind was notified on December 4, 2025, of non-compliance due to its share price being below $1 for over 30 consecutive trading days, and this compliance restoration is expected to enhance investor confidence and attract more capital inflow.
- Market Reaction Expectations: With the restoration of compliance, Clearmind is likely to improve its market image and bolster investor confidence in its future growth potential, particularly in light of its commitment to developing novel psychedelic treatment solutions.
- Strategic Development Focus: Clearmind is currently focused on developing neuroplastic drugs targeting under-treated health issues and will continue to seek patent protection to enhance its intellectual property portfolio, further strengthening its competitiveness in the biotech sector.
See More
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Regained: Clearmind Medicine received confirmation from Nasdaq on December 30, 2025, that its share price exceeded $1 for the last 10 consecutive trading days, thereby regaining compliance with Nasdaq Listing Rule 5550(a)(2) and resolving previous compliance issues.
- Price Fluctuation Context: The company was notified on December 4, 2025, of non-compliance due to its common shares closing below $1 for over 30 consecutive trading days, highlighting market concerns regarding its stock price volatility.
- Future Growth Potential: Clearmind focuses on developing novel neuroplastogen-derived therapeutics, particularly for alcohol use disorder, which is expected to attract more investor interest in its innovative treatment solutions, further stabilizing and potentially increasing the company's stock price.
- Intellectual Property Strategy: The company currently holds 19 patent families and 31 granted patents, with plans to seek additional patents to enhance its market competitiveness, demonstrating a long-term strategic vision in the biotechnology sector.
See More
Clearmind Medicine Advances CMND-100 Clinical Trials for Alcohol Use Disorder
- Clinical Trial Progress: Clearmind successfully initiated its FDA-approved Phase I/IIa trial for CMND-100 at prestigious institutions like Yale and Johns Hopkins, achieving first-in-human dosing and demonstrating a favorable safety profile, marking a significant advancement in treating Alcohol Use Disorder.
- Safety Endorsement: The Data and Safety Monitoring Board unanimously approved the continuation of the clinical trial, reinforcing CMND-100's safety profile and laying a solid foundation for future data readouts, which boosts investor confidence.
- Global Footprint Expansion: Clearmind strengthened its intellectual property portfolio with multiple international patent filings targeting various indications, including weight loss and depression, showcasing the company's strategic positioning across multiple therapeutic areas.
- Future Outlook: Looking ahead to 2026, Clearmind aims to advance its pipeline, generate additional clinical data, and explore strategic opportunities to maximize shareholder value and patient impact, demonstrating its long-term commitment to the market.
See More
